Novel Biopolymers as Implant Matrix for the Deliveryof Ciprofloxacin: Biocompatibility, Degradation, and In Vitro Antibiotic Release

Fulzele, S. V.; Satturwar, P. M.; Dorle, A. K.

doi:10.1002/jps.20730

Cited by 15 publications

(8 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rosin biomaterias have excellent biocompatibility and degradation features, and film-forming ability (Fulzele et al 2003). They show potential as components in film-based drug delivery systems and dosage technology (Satturwar et al 2005;Fulzele et al 2007). …”

Section: Pine Resinmentioning

confidence: 99%

“…It is a brittle, transparent, glassy solid produced by heating fresh liquid resin to vaporize the volatile liquid terpene components. Rosin and rosin derivatives have been pharmaceutically evaluated as microencapsulating materials and as anhydrous binding agents in tablets (Fulzele et al 2002(Fulzele et al , 2007Pathak and Dorle 1990;Sahu et al 1999;Satturwar et al 2004;Lee et al 2005). Rosin biomaterias have excellent biocompatibility and degradation features, and film-forming ability (Fulzele et al 2003).…”

Section: Pine Resinmentioning

confidence: 99%

See 1 more Smart Citation

Forest Products with Health-Promoting and Medicinal Properties

Gallis¹,

Stefano²,

Moutsatsou³

et al. 2010

Forests, Trees and Human Health

View full text Add to dashboard Cite

Forests are a rich renewable source of health-promoting and medicinal products. Not only the trees but also berries, nuts and mushrooms in forests contain a multitude of natural bioactive compounds which can be used in health-promoting products and medicines. In addition to the main structural components that trees contain, namely cellulose, hemicelluloses and lignin, thousands of bioactive compounds have been identified. Forest products have always had a key role in traditional medicine which continues to be of great importance, especially in developing countries. In the industrialized countries, the pharmaceutical industry is again increasingly looking at

show abstract

Section: Pine Resinmentioning

confidence: 99%

Section: Pine Resinmentioning

confidence: 99%

Forest Products with Health-Promoting and Medicinal Properties

Gallis¹,

Stefano²,

Moutsatsou³

et al. 2010

Forests, Trees and Human Health

View full text Add to dashboard Cite

show abstract

“…Although a number of research articles have been published on the controlled release of antibiotics given systemically or as postoperative implants, few reports are associated with controlled release of antibiotics following pulmonary delivery [130,[202][203][204]. One such study used the encapsulation of nafcillin and levofloxacin in PLGA nanoparticles coated with calcium phosphate, to achieve controlled release of the antibiotics.…”

Section: Mycobacterium Smegmatismentioning

confidence: 99%

A New Era of Pulmonary Delivery of Nano-antimicrobial Therapeutics to Treat Chronic Pulmonary Infections

Merchant

Buckton²,

Taylor³

et al. 2016

CPD

View full text Add to dashboard Cite

Pulmonary infections may be fatal especially in immunocompromised patients and patients with underlying pulmonary dysfunction, such as those with cystic fibrosis, chronic obstructive pulmonary disorder, etc. According to the WHO, lower respiratory tract infections ranked first amongst the leading causes of death in 2012, and tuberculosis was included in the top 10 causes of death in low income countries, placing a considerable strain on their economies and healthcare systems. Eradication of lower respiratory infections is arduous, leading to high healthcare costs and requiring higher doses of antibiotics to reach optimal concentrations at the site of pulmonary infection for protracted periods. Hence direct inhalation to the respiratory epithelium has been investigated extensively in the past decade, and seems to be an attractive approach to eradicate and hence overcome this widespread problem. Moreover, engineering inhalation formulations wherein the antibiotics are encapsulated within nanoscale carriers could serve to overcome many of the limitations faced by conventional antibiotics, like difficulty in treating intracellular pathogens such as mycobacteria spp. and salmonella spp., biofilmassociated pathogens like Pseudomonas aeruginosa and Staphylococcus aureus, passage through the sputum associated with disorders like cystic fibrosis and chronic obstructive pulmonary disorder, systemic side effects following oral/parenteral delivery and inadequate concentrations of antibiotic at the site of infection leading to resistance. Encapsulation of antibiotics in nanocarriers may help in providing a protective environment to combat antibiotic degradation, confer controlled-release properties, hence reducing dosing frequency, and may increase uptake via specific and non-specific targeting modalities. Hence nanotechnology combined with direct administration to the airways using commercially available delivery devices, is a highly attractive formulation strategy to eradicate microorganisms from the lower respiratory tract, which might otherwise present opportunities for multi-drug resistance.

show abstract

“…Previous studies have examined the in vitro/in vivo correlation (IVIVC) for various other drug delivery systems, suggesting that the IVIVC varies with each compound and polymer matrix (Wang et al 1996). It is hypothesized that this is due in part to the foreign body response (Fulzele et al 2007). As other researchers have concluded, more sophisticated in vitro models mimicking drug release under in vivo conditions are necessary for parenteral depot formulations, specifically for risperidone implant configurations (Schliecker et al 2004).…”

Section: Critical Issues and Future Directionsmentioning

confidence: 99%

In vitro and in vivo demonstration of risperidone implants in mice

Rabin

Liang

Ehrlichman

et al. 2008

Schizophrenia Research

View full text Add to dashboard Cite

Background-Nonadherence with medication is a critical limitation in current long-term treatment of schizophrenia and a primary factor in poor quality-of-life outcomes. However, few treatments have addressed this shortcoming using an implantable drug delivery approach. The goal of this study was to provide in vitro and in vivo proof of concept for a long-term implantable risperidone delivery system in mice.

show abstract

Novel Biopolymers as Implant Matrix for the Deliveryof Ciprofloxacin: Biocompatibility, Degradation, and In Vitro Antibiotic Release

Cited by 15 publications

References 36 publications

Forest Products with Health-Promoting and Medicinal Properties

Forest Products with Health-Promoting and Medicinal Properties

A New Era of Pulmonary Delivery of Nano-antimicrobial Therapeutics to Treat Chronic Pulmonary Infections

In vitro and in vivo demonstration of risperidone implants in mice

Contact Info

Product

Resources

About